Phaseline

Companies › Rivus Pharmaceuticals

Rivus Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Gastroenterology, Metabolic and endocrine; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HU6–Phase 2Non-Alcoholic Fatty Liver Disease; MASH - Metabolic Dysfunction-Associated SteatohepatitisFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05979779HU6Phase 2Non-Alcoholic Fatty Liver DiseaseGastroenterologyJan 2025
NCT07491458HU6Phase 2MASH - Metabolic Dysfunction-Associated SteatohepatitisMetabolic and endocrineFeb 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Eccogene Visirna Therapeutics HK Rare Thyroid Therapeutics International Eddingpharm (Zhuhai) Ribotek Biopharmaceuticals (Shandong)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.